Journey Clinical, Inc.

Journey Clinical, Inc. is a US-based company that specializes in Ketamine-Assisted Psychotherapy (KAP), offering innovative mental health treatment through the unique combination of ketamine and psychotherapy provided by licensed professionals. Journey Clinical, Inc. was founded in 2020 in New York, US.

The company focuses on delivering mental health solutions through Ketamine-Assisted Psychotherapy. The founders, Jonathan Sabbagh and Myriam Barthes, leverage the latest in mental health treatment to address various psychological conditions. The company has successfully raised USD 11. 5 mn in Seed funding, co-led by Union Square Ventures and Fifty Years, with participation from other investors.

Journey Clinical has completed 2 deals to date, with its most recent deal occurring on October 28, 2022. As of now, the company is valued at USD 27. 04 mn. Journey Clinical specializes in providing Ketamine-Assisted Psychotherapy (KAP), which integrates off-label ketamine treatment with specialized psychotherapy aimed at addressing underlying mental health issues such as depression and anxiety.

The company collaborates with thousands of licensed therapists across various states, ensuring tailored care for patients. Their service delivery spans multiple states including California, Colorado, Florida, New York, and more, facilitating access to innovative mental health treatment options. Journey Clinical generates revenue through partnerships with licensed mental health practitioners who offer KAP to their patients. Their business model is founded on collaborations that allow therapists to access resources for screening, prescriptions, and medication management.

Revenue is derived from service fees paid by therapists for utilizing the platform, structured around subscription services and per-transaction fees linked to treatments administered, thereby supporting both therapists and patients alike. In October 2022, Journey Clinical, Inc. secured USD 11. 5 mn in Seed funding, which will be utilized to expand product services across the US.

The company plans to enhance its offerings and reach new geographic markets, although specific regions for expansion have not been disclosed. This funding aims to bolster their existing services and improve access to Ketamine-Assisted Psychotherapy for a broader patient base.